Cosmos Health Inc. functions as a vertically integrated pharmaceutical firm, providing its own line of branded and generic medicines, nutraceuticals, non-prescription drugs, ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $-0.05 · Revenue $20.89M · 1 analysts
Est. EPS $-0.03 · Revenue $22.97M · 1 analysts
Est. EPS $-0.21 · Revenue $80.80M · 1 analysts
Est. EPS $0.00 · Revenue $26.10M
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $65.3M | +19.9% | +5.9% |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $-19.1M | -18.3% | -117.0% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | +12.1% | +52.7% | +3.3% |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | -25.3% | +11.3% | -26.5% |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | -29.3% | +1.4% | -104.9% |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $-8.5M | -4.5% | -65.2% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | -13.0% | +12.8% | -56.0% |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 108.4% | +124.9% | -12.1% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 1.00x | +1.5% | -2.8% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $65.5M | +20.6% | -1.5% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | -0.63 vs -0.34 | -85.3% | -0.10 vs -0.10 | 0.0% |
| Revenue Surprise | $65.3M vs $64.4M | +1.4% | $19.0M vs $19.0M | 0.0% |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Jul 30, 2026 | Siokas Grigorios | director, 10 percent owner, officer: Chief Executive Officer | Common Stock, par value $.001 | A | 349,825 | $0.20 |
| Jul 29, 2026 | Terzis Georgios | officer: Chief Financial Officer | Common Stock, par value $.001 | A | 328,407 | $0.18 |
| Jul 29, 2026 | Siokas Grigorios | director, 10 percent owner, officer: Chief Executive Officer | Common Stock, par value $.001 | A | 766,284 | $0.18 |
| Jun 16, 2026 | Terzis Georgios | officer: Chief Financial Officer | Common Stock, par value $.001 | A | 168,135 | $0.25 |
| Jun 11, 2026 | Siokas Grigorios | director, 10 percent owner, officer: Chief Executive Officer | Common Stock, par value $.001 | A | 218,447 | $0.21 |
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Grigorios Siokas | Chairman & Chief Executive Officer | USD 2,880,000 | Male | 1965 | Active |
Georgios Terzis | Chief Financial Officer | USD 348,235 | Male | 1983 | Active |
Nikolaos Bardakis | Chief Operating Officer | USD 39,375 | Male | 1969 | Active |
Demetrios G. Demetriades | Secretary & Independent Director | USD 15,000 | Male | 1965 | Active |
Dimitrios Trafalis | Head of Oncology | — | — | — | Active |
A Comprehensive Corporate Summary — January 1, 2026 through August 31, 2026 Revenue record set three consecutive quarters: FY2025 $65.3M (+20%) → Q1 2026 $17.93M (+31%) → Q2 2026 $18.99M (+28.8%) → H1 2026 $36.91M (+29.7%). Annualized adjusted run-rate exceeds $75M.
$8 million senior secured ATW convertible note satisfied, together with all accrued interest, twelve months ahead of its August 2027 maturity and eliminating any further dilution Simplified capital structure, with no effective shelf registration statement or ATM program, and no structured warrants or variable interest rate instruments without a floor Operating cash requirements reduced by more than 30%, reflecting revenue growth, operating efficiencies, improved operating leverage and cost control Strong liquidity position, with a diversified asset base supporting the Company's next growth phase and Bitcoin holdings now in a gain position following recent market strength $5.0 million share repurchase program underway, following record second-quarter and first-half revenue, with momentum continuing into Q3 2026 CHICAGO, Aug. 28, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") ( NASDAQ: COSM ), a diversified, vertically integrated global healthcare group, today announced that its $8.0 million senior secured convertible ATW note has been retired, and provided an update on its capital structure and operating cash requirements. These financial milestones come at a time of accelerating growth, with Cosmos Health delivering its highest second-quarter and first-half revenue in Company history, contribution from every core division and momentum continuing into Q3 2026.
Cosmos Health Projects Over $6M in Annual Revenue and $4.3M in Gross Profit from Oliv18™ Across the U.S. Cardiovascular Health and Antioxidant Categories.
Cosmos Health Enters Saudi Arabia. Signs Exclusive Distribution Agreement With Innova Healthcare; Secures Purchase Order of 126,000 Sky Premium Life Units.
Highest Q2 and H1 revenue in Company history, reflecting strength across all core segments and reaching a new milestone with an adjusted annualized revenue run-rate exceeding $75 million Continued progress toward profitability targets, with adjusted gross profit reaching approximately $7.4 million on an annualized basis, adjusted gross margin expanding 165 basis points to 9.54%, and adjusted EBITDA improving 13.8% Demonstrated operating leverage and disciplined inventory management, with Q2 operating expenses growing at roughly half the rate of revenue and first-half inventory down 21.8% despite nearly 30% revenue growth Strengthened balance sheet, with total liabilities decreasing 13.3% by $6.27 million, stockholders' equity rising 12.2% to $20.67 million, and the liabilities-to-assets ratio improving by 550 basis points Liquid assets of $4.15 million, comprising cash, marketable securities and digital assets Share repurchase program actively underway as record momentum continues into Q3 2026 CHICAGO, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today reported financial results for the second quarter and six months ended June 30, 2026. Second Quarter and First Half 2026 Financial Highlights Income Statement Cosmos Health delivered its highest second-quarter and first-half revenue in Company history, with growth contributed by every core division.
